Compare FDP & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FDP | STOK |
|---|---|---|
| Founded | 1886 | 2014 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 1999 | 2019 |
| Metric | FDP | STOK |
|---|---|---|
| Price | $41.01 | $35.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $39.20 |
| AVG Volume (30 Days) | 251.2K | ★ 740.6K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.88% | N/A |
| EPS Growth | N/A | ★ 92.73 |
| EPS | ★ 1.88 | N/A |
| Revenue | ★ $4,322,300,000.00 | $184,420,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.14 | $77.49 |
| P/E Ratio | $22.13 | ★ N/A |
| Revenue Growth | 0.98 | ★ 404.50 |
| 52 Week Low | $31.70 | $7.34 |
| 52 Week High | $43.58 | $40.22 |
| Indicator | FDP | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 46.42 | 56.82 |
| Support Level | $39.86 | $30.34 |
| Resistance Level | $43.30 | $39.00 |
| Average True Range (ATR) | 1.16 | 1.99 |
| MACD | -0.04 | 0.31 |
| Stochastic Oscillator | 40.65 | 79.13 |
Fresh Del Monte Produce Inc is an integrated producer, marketer & distributor of fresh-cut fruit & vegetables. It operates in three segments, Fresh and value-added products segment, which includes pineapples, fresh-cut fruit, fresh-cut vegetables, melons, vegetables, non-tropical fruit, other fruit and vegetables, avocados, and prepared foods, Banana segment & Other products and services segment, including the third-party freight & logistic services business & the Jordanian poultry and meats business. The majority is from the Fresh and value-added products segment. Geographically, it operates in North America, Europe, Asia, the Middle East, and Other, out of which the highest is from North America.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.